Letters Primary percutaneous coronary intervention

Authors’ reply to Sharvill and Beales

BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.j5614 (Published 11 January 2018) Cite this as: BMJ 2018;360:j5614
  1. Hasnain M Dalal, honorary clinical associate professor1,
  2. Manish M Gandhi, consultant cardiologist2,
  3. Christos Voukalis, clinical research fellow in cardiology3,
  4. Fatima Dalal, FY2 doctor4
  1. 1University of Exeter Medical School (Primary Care), Truro Campus, Truro TR1 3HD, UK
  2. 2Cardiac Department, Royal Devon and Exeter NHS Foundation Trust, Exeter EX2 5DW, UK
  3. 3Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK
  4. 4Queen Elizabeth Hospital, Birmingham B15 2GW, UK
  1. hmdalal{at}doctors.net.uk

We thank Sharvill and Beales for drawing attention to gastroprotection for dyspepsia associated with dual antiplatelet therapy and a higher bleeding risk in elderly people, which we referred to in our article.123 We agree that a proton pump inhibitor or H2 receptor antagonist should be used to reduce the risk of bleeding in patients with a history of bleeding in the upper gastrointestinal tract and should …

View Full Text

Sign in

Log in through your institution

Subscribe